Leprosy Mailing List – October 26, 2017
Ref.: (LML) Promising new leprosy vaccine moves into human trials
From: Ben Naafs, Munnekeburen, the Netherlands
Dear Pieter,
The LML message of ALM and IDRI sounds nice (LML< October 23, 2017). However, in history there have been many claims of this kind. IDRI is notorious in claiming successes in their work for mankind: e.g. Leishmania vaccine, tuberculosis vaccine and the LID test.
It is correct that they acknowledge - without saying so - that only people who can get leprosy will benefit from the vaccine, and that is only 20% of the world population. Also in the past vaccines have been developed for leprosy, though indeed not fully chemical. These vaccines too were effective in the treatment of leprosy.
However, politicians and leprosy NGO's too, only intended to vaccinate against leprosy. Since the vaccines had only a 0-80% effectivity, depending on the type of boosting environmental mycobacteria present in the vicinity, they lost confidence. Though, in infected patients it had a definite effect, in some patients causing reversal reactions, curing others, and diminishing the frequency and severity of ENL.
The new vaccine IDRI and ALM introduce needs investigation into all those effects the former vaccines had.
Above all I wonder whether their vaccine will do much better.
With regards
Ben
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
No comments:
Post a Comment